| Budget Amount *help |
¥42,640,000 (Direct Cost: ¥32,800,000、Indirect Cost: ¥9,840,000)
Fiscal Year 2014: ¥13,910,000 (Direct Cost: ¥10,700,000、Indirect Cost: ¥3,210,000)
Fiscal Year 2013: ¥14,560,000 (Direct Cost: ¥11,200,000、Indirect Cost: ¥3,360,000)
Fiscal Year 2012: ¥14,170,000 (Direct Cost: ¥10,900,000、Indirect Cost: ¥3,270,000)
|
|---|
| Outline of Final Research Achievements |
We have examined neuroprotective effects of inhibitors for ATP activity of VCP on glaucoma and retinal degeneration animal models. The inhibitors suppressed decrease of the retinal ganglion cells and thinning of the retinal nerve fiber layer in NMDA-induced acute injury model, DBA2J, and GLAST knockout mice. The inhibitors suppressed decrease of photoreceptor cells and worsening of vusual function in rd10, rd12 mice and model rabbits of retinitis pigmentosa. The VCP ATPase inhibitors might protect neural cells by reducing decrease of ATP and ER stress in the cells.
The VCP ATPase inhibitors may be a new treatment for ocular diseases.
|
